NOVOMEDLINK™
  1. Activella®

    (estradiol/norethindrone acetate tablets)

  2. Vagifem®

    (estradiol vaginal tablets)

  3. Levemir®

    (insulin detemir [rDNA origin] injection)

  4. Norditropin®

    (somatropin (rDNA origin) injection)

  5. NovoLog®

    (Insulin aspart [rDNA origin] injection)

  6. NovoLog® Mix 70/30

    (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])

  7. NovoSeven®

    (Coagulation Factor VIIa [Recombinant])

Starting Your Patients With NovoLog® FlexPen®

NovoLog® FlexPen® is a convenient add-on therapy for effective glycemic control

Transitioning from a basal insulin to a basal–bolus regimen38

Dosage regimens of NovoLog® will vary among patients and should be determined by the healthcare professional familiar with the patient's metabolic needs, eating habits, and other lifestyle variables. In addition, the dose must be individualized for each patient based on blood glucose monitoring.

†SMBG = self-monitored blood glucose.

  1. NovoLog® (Insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

    NovoLog® Important Safety Information

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. Because of the fast onset of action, the injection of NovoLog® should be immediately followed by a meal. Because of the short duration of action of NovoLog®, patients with diabetes also require a longer-acting insulin to maintain adequate glucose control. NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Hypoglycemia is the most common adverse effect of insulin therapy, including NovoLog®.

    Any change in insulin should be made cautiously and only under medical supervision. The time course of action of insulin and insulin analogs such as NovoLog® may vary considerably in different individuals or within the same individual. A1C levels did not differ between patients treated with regular human insulin and those treated with NovoLog®.

    Differences in pharmacokinetics and pharmacodynamics between NovoLog® and regular human insulin are not associated with differences in overall glycemic control.

    In controlled clinical trials, allergic reactions were reported in 3 of 735 patients (0.4%) who received regular human insulin and 10 of 1394 patients (0.7%) who received NovoLog®. Levels of antibodies that cross-react with human insulin and insulin aspart were transiently increased in type 1 patients treated with NovoLog® compared with regular human insulin and no longer evident at 12 months of treatment. As with other insulins, NovoLog® dose requirements may be reduced in the presence of renal impairment or hepatic dysfunction.

    Pump or infusion set malfunctions or insulin degradation can lead to hyperglycemia and ketosis in a short time because of the small subcutaneous depot of insulin. This is especially pertinent for rapid-acting insulin analogs that are more rapidly absorbed and have shorter durations of action. These differences may be particularly relevant when patients are switched from multiple injection therapy or infusion with buffered regular insulin.

    Please see Prescribing Information.

Levemir®, NovoLog®, NovoLog® Mix 70/30, FlexPen® and Norditropin® are registered trademarks of Novo Nordisk A/S. NovoSeven® is a registered trademark of Novo Nordisk Health Care AG. Activella® 1.0 mg/0.5 mg and Activella® 0.5 mg/0.1 mg and Vagifem® are registered trademarks of Novo Nordisk FemCare AG.